{"id":"https://openalex.org/W2563544855","doi":"https://doi.org/10.1158/1538-7445.am2015-3670","title":"Abstract 3670: NanoPARPi inhibitors for ovarian and prostate cancer therapy","display_name":"Abstract 3670: NanoPARPi inhibitors for ovarian and prostate cancer therapy","publication_year":2015,"publication_date":"2015-08-01","ids":{"openalex":"https://openalex.org/W2563544855","doi":"https://doi.org/10.1158/1538-7445.am2015-3670","mag":"2563544855"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2015-3670","doi":"https://doi.org/10.1158/1538-7445.am2015-3670","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-3670","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020321227","display_name":"Shifalika Tangutoori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shifalika Tangutoori","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027990829","display_name":"Paige Bladwin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paige Bladwin","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072335433","display_name":"Anders \u00d6hman","orcid":"https://orcid.org/0000-0002-3146-9448","observed_orcids":["https://orcid.org/0000-0002-3146-9448"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anders Ohman","raw_affiliation_strings":["2Brigham and Women's hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Brigham and Women's hospital, Boston, MA;","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089283632","display_name":"Houari Korideck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Houari Korideck","raw_affiliation_strings":["3Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088554776","display_name":"Robert A. Cormack","orcid":"https://orcid.org/0000-0001-5553-9984","observed_orcids":["https://orcid.org/0000-0001-5553-9984"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Cormack","raw_affiliation_strings":["3Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011691171","display_name":"Daniela M. Dinulescu","orcid":"https://orcid.org/0009-0003-5711-8210","observed_orcids":["https://orcid.org/0009-0003-5711-8210"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniela Dinulescu","raw_affiliation_strings":["2Brigham and Women's hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Brigham and Women's hospital, Boston, MA;","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039898021","display_name":"Mike G. Makrigiorgos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Makrigiorgos","raw_affiliation_strings":["3Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101987852","display_name":"Srinivas Sridhar","orcid":"https://orcid.org/0000-0003-1605-0734","observed_orcids":["https://orcid.org/0000-0003-1605-0734"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srinivas Sridhar","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"15_Supplement","first_page":"3670","last_page":"3670"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8237000107765198,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8237000107765198,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.16769999265670776,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.949999988079071},{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9829999804496765},{"id":"https://openalex.org/keywords/nanoparticle-drug-delivery","display_name":"nanoparticle drug delivery","score":0.8949999809265137},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.847000002861023},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.9100000262260437},{"id":"https://openalex.org/keywords/cisplatin-combination-therapy","display_name":"cisplatin combination therapy","score":0.8230000138282776},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.8159999847412109},{"id":"https://openalex.org/keywords/pten-loss","display_name":"PTEN loss","score":0.7179999947547913},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.8109999895095825},{"id":"https://openalex.org/keywords/poly-adp-ribosyl-ation","display_name":"poly(ADP-ribosyl)ation","score":0.515999972820282},{"id":"https://openalex.org/keywords/tumor-xenograft-models","display_name":"tumor xenograft models","score":0.5690000057220459},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.5680000185966492},{"id":"https://openalex.org/keywords/drug-toxicity-reduction","display_name":"drug toxicity reduction","score":0.328000009059906},{"id":"https://openalex.org/keywords/combination-therapy-synergy","display_name":"combination therapy synergy","score":0.3840000033378601},{"id":"https://openalex.org/keywords/isobologram-analysis","display_name":"isobolographic analysis","score":0.5379999876022339}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.970363974571228},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7573692798614502},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6607557535171509},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6319144368171692},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5866514444351196},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5821625590324402},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.5238328576087952},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44448423385620117},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4331849217414856},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42723941802978516},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.34502145648002625},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.3311884105205536},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.27687856554985046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19503140449523926},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.1279420554637909},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06170755624771118},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2015-3670","doi":"https://doi.org/10.1158/1538-7445.am2015-3670","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-3670","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1992065025","https://openalex.org/W2566054689","https://openalex.org/W2403569294","https://openalex.org/W2399980135","https://openalex.org/W2079215618","https://openalex.org/W7070521202","https://openalex.org/W2504216116","https://openalex.org/W7060780813","https://openalex.org/W6992992140","https://openalex.org/W2528345273"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Poly":[2],"ADP":[3],"Ribose":[4],"Polymerase":[5],"(PARP)":[6],"inhibitor":[7,271],"therapy":[8,40,185,219],"exploits":[9],"a":[10,46,67,71,180,350],"synthetic":[11],"lethality":[12],"strategy":[13],"in":[14,21,41,101,325,353],"cancers":[15,103],"specifically":[16,77],"endowed":[17],"with":[18,112,143,167,220,307,327,334,356],"inherent":[19],"damage":[20],"DNA":[22],"repair":[23],"or":[24,170],"transcription":[25],"pathways.":[26],"Olaparib":[27,168],"and":[28,54,62,99,107,113,123,129,145,151,165,173,196,217,241,342,375,379,408],"BMN-673":[29,63,171],"are":[30,35,336],"potent":[31,269],"PARP":[32,149,243,270],"inhibitors":[33,150,251,310,405],"that":[34],"currently":[36],"indicated":[37],"for":[38,45,59,74,95,207,372,406,424],"chronic":[39],"several":[42,102,133,187,364,382],"clinical":[43],"trials":[44],"variety":[47],"of":[48,147,183,214,228,233,239,415,420],"cancers.":[49,230],"Here":[50],"we":[51],"report":[52],"novel":[53],"well":[55],"characterized":[56],"nanoformulations":[57],"customized":[58,194],"olaparib":[60],"(NanoOlaparib)":[61],"(NanoBMN-673),":[64],"thus":[65],"enabling":[66,381],"platform":[68,222],"which":[69,272],"provides":[70],"safe":[72],"vehicle":[73],"intravenous":[75],"delivery":[76],"targeted":[78],"to":[79,203,285,305],"the":[80,84,96,115,148,152,267,354,373,416,421],"tumor,":[81],"thereby":[82],"increasing":[83],"bioavailability":[85],"while":[86],"reducing":[87],"systemic":[88],"toxicity.":[89],"Our":[90],"nanoplatform":[91],"is":[92,154,273],"also":[93],"tailored":[94],"combinatorial":[97],"chemotherapy":[98],"radio-sensitization":[100],"including":[104],"prostate,":[105],"ovarian":[106,257,407],"breast":[108],"cancer":[109,134,258,300,410],"cell":[110,135,188,262,316],"lines":[111,189,281],"without":[114],"BRCA":[116,278],"mutations.":[117],"Methods:":[118],"Two":[119],"nanoparticle":[120,221],"formulations,":[121,235],"NanoOlaparib":[122,341],"NanoBMN-673":[124,321],"have":[125,344],"been":[126,345],"successfully":[127,346],"formulated":[128],"tested":[130],"invitro":[131],"on":[132,186,225,254,277],"lines.":[136],"The":[137,200,212,231],"initial":[138],"combination":[139,215,326,383],"studies":[140,320,333],"were":[141,190,198,252,302],"performed":[142],"Cisplatin":[144,174],"each":[146],"nanoformulation":[153],"defined":[155],"by":[156,237,246],"nanoparticles":[157],"\u223c120":[158],"nm":[159],"diameter,":[160],"zeta":[161],"potential":[162],"\u223c":[163],"+30mV,":[164],"loaded":[166],"(18mM)":[169],"(200\u03bcM)":[172],"(\u223c3.3mM).":[175],"Dose":[176],"response":[177],"curves":[178],"over":[179],"dynamic":[181],"range":[182],"nanoPARPi":[184,234,309],"generated":[191],"using":[192,210,260],"various":[193,261],"assays":[195],"EC50's":[197],"determined.":[199],"synergism":[201],"due":[202],"radiosensitization":[204,306,360],"was":[205,223,244,266,361],"studied":[206],"both":[208,308,357],"therapies":[209],"isobolograms.":[211],"efficacy":[213,324,355],"PARPi":[216],"Pt":[218],"determined":[224,245],"GEMM":[226,291],"models":[227],"endometrial":[229],"functionality":[232],"reflected":[236],"inhibition":[238],"PARylation,":[240],"cleaved":[242],"immunoflourescence":[247],"assays.":[248,264],"Results:":[249],"NanoPARPi":[250,404],"assayed":[253],"atleast":[255],"8":[256],"cells":[259,280,294,301],"based":[263],"NanoBMN":[265],"most":[268],"not":[274],"functionally":[275],"dependent":[276],"sensitive":[279,287],"whereas":[282],"nanoOlaparib,":[283],"seems":[284],"be":[286],"towards":[288],"triple":[289],"negative":[290],"derived":[292],"Ovarian":[293],"(403,":[295],"404).":[296],"PTEN":[297],"deficient":[298],"prostate":[299,409],"more":[303],"susceptible":[304],"(Olaparib,":[311],"BMN-673),":[312],"achieving":[313],"significant":[314,351],"long-term":[315],"kill.":[317],"In":[318,331],"all":[319],"showed":[322],"better":[323],"radiation":[328],"than":[329],"NanoOlaparib.":[330],"vivo":[332],"irradiation":[335],"underway.":[337],"Conclusions:":[338],"Robust":[339],"nanoformulations,":[340],"nanoBMN-673":[343,376],"demonstrated.":[347],"We":[348],"observed":[349,362],"enhancement":[352],"nanoformulations.":[358],"Strong":[359],"after":[363],"days.":[365],"These":[366],"results":[367],"imply":[368],"an":[369],"important":[370],"role":[371],"nanoOlaparib":[374],"as":[377],"chemo":[378],"radio-sensitizers":[380],"therapeutic":[384],"approaches.":[385],"Citation":[386],"Format:":[387],"Shifalika":[388],"Tangutoori,":[389],"Paige":[390],"Bladwin,":[391],"Anders":[392],"Ohman,":[393],"Houari":[394],"Korideck,":[395],"Robert":[396],"Cormack,":[397],"Daniela":[398],"Dinulescu,":[399],"Mike":[400],"Makrigiorgos,":[401],"Srinivas":[402],"Sridhar.":[403],"therapy.":[411],"[abstract].":[412],"In:":[413],"Proceedings":[414],"106th":[417],"Annual":[418],"Meeting":[419],"American":[422],"Association":[423],"Cancer":[425,435],"Research;":[426],"2015":[427],"Apr":[428],"18-22;":[429],"Philadelphia,":[430],"PA.":[431],"Philadelphia":[432],"(PA):":[433],"AACR;":[434],"Res":[436],"2015;75(15":[437],"Suppl):Abstract":[438],"nr":[439],"3670.":[440],"doi:10.1158/1538-7445.AM2015-3670":[441]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2017-01-06T00:00:00"}